Domainex's newsletter brings you up to speed on the latest announcements from the team.
No images? Click here
Domainex newsletter
All the latest news and industry insights from the Domainex team
Tom Mander, CEO
Reflecting on the new year
We’re already into February (where does the time go?) but I hope everyone is having a good start to the year. 2021 was a record year for Domainex: growing as a company, celebrating our 20th anniversary and being awarded ‘Best Drug Discovery CRO’ were just a few highlights. 2022 promises to be even better. We have just announced our collaboration with Parkinson’s UK, which will focus on developing small molecule therapies targeting neuroinflammation. Also, last month we announced the exciting news that Queen’s University Belfast has entered into a collaboration and licensing agreement with Ipsen to progress a FLIP inhibitor programme which was supported by Domainex. There is more exciting news to come – watch this space!
Thank you to our excellent team for all their hard work during 2021 and the beginning of 2022. As the new year gets into full swing, we can’t wait to support many more innovative drug discovery projects.
I wish you all the best for 2022.
Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s
Domainex and Parkinson’s UK have announced a collaboration focused on developing small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s. Domainex will provide fully integrated drug discovery services including assay biology, medicinal and computational chemistry.
Queen’s University Belfast enters agreement with Ipsen in FLIP inhibitor project supported by Domainex
The FLIP inhibitor programme has been supported by Domainex since its inception, including providing integrated medicinal chemistry services and assistance in securing a Wellcome Trust Seeding Drug Discovery award. Queen’s has now entered a collaboration and licensing agreement with Ipsen to research, develop, manufacture and commercialise FLIP inhibitors.
One Nucleus Genesis
Rachel Pearce attended One Nucleus Genesis on behalf of Domainex and discussed science in person with old and new acquaintances.
Domainex wins Best Drug Discovery CRO award
Domainex was awarded the Best Drug Discovery CRO 2021 in the Healthcare and Pharmaceutical Awards, marking two years of recognition in this sector.
Medicinal Chemistry in Review
Factor XIa selective inhibitors as potential new anticoagulants for the treatment of thrombotic diseases.
Developing your career with Domainex
Welcome to Carlos Turrado García (Senior Scientist II, Chemistry), Carmina Micelli (Senior Scientist I, Protein Science), Fruzsina Hobor (Senior Scientist II, Protein Science), Hayley Jackson (Scientist, Protein Science), Ian Winfield (Team Leader, Assay Biology), Nima Abbasian (Senior Scientist I, Assay Biology), Phil Leonard (Team Leader, Protein Science) and Robina Akhtar (Financial Controller) who have all recently joined the Domainex team. And a huge congratulations to those of our team who have recently been promoted.
Upcoming events
Biotechgate Digital Partnering: Virtual Business Development & Licensing Event
7th-11th February 2022 | Virtual
Providing a platform for business development in the field of licensing and collaboration.
8th RSC-BMCS Fragment-based Drug Discovery Meeting (Fragments 2022)
27th March 2022 | Cambridge, UK and Virtual
A look into fragment-based Drug Discovery case studies that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes.
ELRIG Research and Innovation
29th March 2022 | Oxford, UK
A conference discussing how cutting edge science continues to be identified and exploring how emerging technologies will enable this science to be translated into successful therapeutics.
